NEW DELHI – The WHO has rapped yet another Indian clinical research organization (CRO) for "critical lapses and major deviations" during the conduct of clinical trials, bringing the spotlight back to the need for Indian pharma firms and CROs to pull up their socks over stringent adherence to trial protocols.